C

Concord Drugs Ltd
BSE:538965

Watchlist Manager
Concord Drugs Ltd
BSE:538965
Watchlist
Price: 70.1 INR 0.23% Market Closed
Market Cap: ₹701m

Operating Margin

6.1%
Current
Improving
by 0.4%
vs 3-y average of 5.7%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
6.1%
=
Operating Income
₹28.6m
/
Revenue
₹471.6m

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
6.1%
=
Operating Income
₹28.6m
/
Revenue
₹471.6m

Peer Comparison

Country Company Market Cap Operating
Margin
IN
Concord Drugs Ltd
BSE:538965
701m INR
Loading...
US
Eli Lilly and Co
NYSE:LLY
954.9B USD
Loading...
US
Johnson & Johnson
NYSE:JNJ
546.2B USD
Loading...
CH
Roche Holding AG
SIX:ROG
269.6B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
208B GBP
Loading...
CH
Novartis AG
SIX:NOVN
217.7B CHF
Loading...
US
Merck & Co Inc
NYSE:MRK
265.4B USD
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.7T DKK
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...
US
Pfizer Inc
NYSE:PFE
147.6B USD
Loading...
FR
Sanofi SA
PAR:SAN
93.9B EUR
Loading...

Market Distribution

In line with most companies in India
Percentile
44th
Based on 5 437 companies
44th percentile
6.1%
Low
-153 833.3% — 2.7%
Typical Range
2.7% — 13.2%
High
13.2% — 9 977%
Distribution Statistics
India
Min -153 833.3%
30th Percentile 2.7%
Median 7.3%
70th Percentile 13.2%
Max 9 977%

Concord Drugs Ltd
Glance View

Market Cap
701m INR
Industry
Pharmaceuticals

Concord Drugs Ltd. engages in the provision of pharmaceutical formulations. The company is headquartered in Hyderabad, Telangana. The company went IPO on 2015-02-23. The firm is engaged in manufacturing of licensed drugs based on the formulations approved. The firm offers finished pharmaceutical formulations, such as injectables (small volume parenteral, dry powders), tissue bio-adhesive, tablets, capsules, liquid orals (syrup & suspension) and dry syrups (powder). The firm also provides ready-to-fill pellets and multiple unit pellets system (MUPS). Its pellets are categorized as gastrointestinal drug pellets, cardiovascular drug pellets, respiratory drug pellets, anti-obesity drug pellets, anti-depressant drug pellets, central nervous system drug pellets, urological drug pellets, anti-microbial, anti-infective and adjuvant drugs pellets, taste mask drug pellets/powder, nutrition and food supplement drug pellets, anti cholesterol drug pellets. The company also provides Iso Amyl 2-Cyano Acrylate, which is a bio-adhesive product.

CONCORD Intrinsic Value
HIDDEN
Show
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
6.1%
=
Operating Income
₹28.6m
/
Revenue
₹471.6m
What is Concord Drugs Ltd's current Operating Margin?

The current Operating Margin for Concord Drugs Ltd is 6.1%, which is above its 3-year median of 5.7%.

How has Operating Margin changed over time?

Over the last 3 years, Concord Drugs Ltd’s Operating Margin has increased from 5.2% to 6.1%. During this period, it reached a low of 2.3% on Sep 30, 2024 and a high of 9.4% on Sep 30, 2023.

Back to Top